On March 1, 2019 Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, reported that it has changed its name to Rakuten Medical, Inc (Press release, Rakuten Aspyrian, MAR 1, 2019, View Source/2019/02/28/rakuten-aspyrian-announces-name-change-to-rakuten-medical/" target="_blank" title="View Source/2019/02/28/rakuten-aspyrian-announces-name-change-to-rakuten-medical/" rel="nofollow">View Source [SID1234533855]). This name more closely reflects the company’s corporate purpose of creating a global biotechnology company integrating research and development with commercial operations in order to develop therapeutics that improve cancer patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are aiming to deliver PIT platform to as many cancer patients and as early as possible worldwide. Our new name that becomes effective today, Rakuten Medical, better aligns with our goal of developing a global brand that resonates within the pharmaceutical and medical device industries," said Mickey Mikitani, chairman and CEO of Rakuten Medical. "Despite our name change, our mission of ‘Conquering cancer, For life’ will not change. We are stronger today than ever before as we continue building the organization necessary to conquer cancer by developing innovative cancer treatments."

For more information, visit View Source

On March 1, 2019 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, reported that it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Friday, March 8, 2019 following release of its year end 2018 financial results (Press release, Oncolytics Biotech, MAR 1, 2019, https://ir.oncolyticsbiotech.com/news/detail/448/oncolytics-biotechr-to-host-conference-call-to-discuss-year-end-financial-results-and-operational-highlights [SID1234533905]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live call may be accessed by dialing (877) 407-9205 for callers in North America. Overseas callers should contact investor relations for the toll-free dial information for their country. A replay of this call will be available approximately two hours after the call is ended at (877) 481-4010, using the replay code 44902 and will be available for one week. A live webcast of the call will be accessible on the Investor Relations page of Oncolytics’ website at www.oncolyticsbiotech.com and will be archived for three months.

On March 1, 2019 Allergan plc (NYSE: AGN) reported that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C. March 1-5, 2019 (Press release, Allergan, MAR 1, 2019, View Source [SID1234533873]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The meeting will be held at the Walter E. Washington Convention Center and the scheduled times (noted in local Eastern Time) for the Allergan presentations are as follows:

Oral Poster Presentations

Botulinum Neurotoxin Type A Directly Affects Sebocytes and Inhibits Induced Lipogenesis

Authors: Hui You, Alex Chernavsky, Sergei Grand, Amy Brideau-Andersen, Birgitte Jacky
Friday, 3/1: 10:00-10:05AM, Hall H, ePoster Presentation Center 1
Protective and Reparative Effects of a Topical Dual Serum System Against UV-Induced Skin Damage

Authors: Elizabeth Makino, Pricilla Tan, Rahul C. Mehta
Saturday, 3/2: 9:45-9:50AM, Hall H, ePoster Presentation Center 1
Environmental protection and rejuvenation from a novel antioxidant dual serum system: A randomized, double-blind, regimen controlled, multi-center study

Authors: Zoe D. Draelos, Elizabeth Makino, Priscilla Tan, Kuniko Kadoya, Audrey Nguyen, Lily Jiang, Rahul C. Mehta
Sunday, 3/3: 9:10-9:15AM, Hall D, ePoster Presentation Center 2
Poster Presentations

Botulinum Neurotoxin Type A Exhibits a Linear Correlation Between Dose, Peak Efficacy and Duration of Effect in Functional Assays

Authors: Greg S. Nicholson, Dave Canty, Amy D. Brideau-Andersen and Ron S. Broide
Available for online viewing during program
Safety and Efficacy of OnabotulinumtoxinA for Treatment of Masseter Muscle Hypertrophy: Results from a Phase 2 Dose-Escalation Study

Authors: Jean Carruthers, Steven Liew, Jason K Rivers, Shyi-Gen Chen, Shannon Humphrey, Elisabeth Lee, Beta Bowen, Mitchell F. Brin
Available for online viewing during program
Clinical Efficacy of a Novel Two-Part Skincare System on Pollution-Induced Skin Damage

Authors: Elizabeth T. Makino, Annie Jain, Priscilla Tan, Audrey Nguyen, Alain Mogac, Kuniko Kadoya
Available for online viewing during program
Evaluation of the Protective Effect of a Topical Serum Against Particles Modeling Atmospheric Pollution

Authors: Elizabeth Makino, Pricilla Tan, Cécile Charmel, Rahul C. Mehta
Available for online viewing during program

On March 1, 2019 Applied DNA Sciences Inc. (NASDAQ: APDN) ("Applied DNA"), a leader in large-scale PCR-based DNA manufacturing, reported that LineaRx, Inc. ("LineaRx"), its wholly-owned subsidiary focused on next-generation biotherapeutics, will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement ("JDA") entered into in September 2018 (Press release, Applied DNA Sciences, MAR 1, 2019, View Source [SID1234533907]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Per the JDA, LineaRx and Takis/Evvivax will jointly develop linear DNA expression amplicons for TK7 and ConTRT, two of Takis/Evvivax’s anti-cancer vaccine candidates, utilizing LineaRx’s validated linear DNA technology. Linear DNA amplicons carrying the DNA sequences for Takis/Evvivax vaccine candidates will be delivered to pre-clinical animal models via Takis/Evvivax’s proprietary electroporation technology.

In 2018, LinearRx and Takis/Evvivax’s collaboration showed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase that is over-expressed in more than 85% of all cancers. "This year we are using ConTRT, an improved version of our telomerase vaccine and a unique personalized approach which includes an epitope-prediction pipeline and a delivery strategy to achieve an extremely effective cancer vaccine over what has been done previously," said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. "Each expression amplicon will undergo rigorous quality subject matter testing, immunogenicity testing, followed by a tumor challenge, with results planned for publication later this year."

"Our collaborations with Takis/Evvivax and other therapy developers are helping to validate LineaRx’s novel technology as a viable alternative to bacterially-produced plasmids, with the potential for increased patient safety and reduced costs, using new quality control protocols for large-scale PCR production at LineaRx. We believe that linear DNA and the establishment of new quality attributes for this new therapeutic field will change the way gene and immune therapies will be performed," stated Dr. James Hayward, president and CEO of Applied DNA. "Our implementation of testing for new quality attributes will support our preparation to approach FDA to seek approval for clinical study. Our know-how in the fields of therapeutic linear DNA production and the standardized PCR platforms in use at LineaRx enable us to create novel expression amplicons. We are extremely pleased with the progress we are making with Takis/Evvivax under our JDA."

On March 1, 2019 MaxCyte, the global cell-based medicines and life sciences company, reported that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement (Press release, MaxCyte, MAR 1, 2019, View Source [SID1234537626]). Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We’re excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte’s versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics," said Doug Doerfler, President & CEO of MaxCyte, Inc.

The expansion of the Kite-MaxCyte relationship builds on an existing research agreement announced in November 2018. Under the terms of the new license agreement, Kite obtains non-exclusive clinical and commercial-use rights to MaxCyte’s cell engineering platform to develop CAR-T therapies, and MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.